{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
vitamin a
to a specific field?
Status:
Investigational
Source:
Diabetes Obes Metab. Mar 2023;25(3):832-843.: Phase 2 Human clinical trial Completed Diabetes Mellitus, Type 2/complications
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Chloralose (alpha-Chloralose, 1,2-O-(2,2,2-Trichloroethylidene)-α-D-glucofuranose) is an avicide, and a rodenticide commonly used for the control of mice and birds. Since its initial description in 1893, alpha-chloralose has undergone extensive pharmacologic evaluation. It has been characterized as a compound possessing potent CNS activity and has been evaluated in humans and animal models for its therapeutic properties. Though the toxicity of the compound prohibits its use as a human therapeutic agent, it has been employed widely as an animal anesthetic in the laboratory setting. α-Chloralose is widely used as an anesthetic in studies of the cerebrovasculature because of its presumed minimal depression of autonomic function. α-Chloralose acts as the positive allosteric modulator of GABA-A receptor and increases the affinity for GABA 5-fold and produced a small increase in the efficacy of GABA. Studies of α-Chloralose interactions with other allosteric modulators determined that α-Chloralose binds to a site on the GABAA receptor complex distinct from the benzodiazepine, neurosteroid and barbiturate sites.
Status:
Investigational
Source:
NCT00454103: Phase 1/Phase 2 Interventional Completed Adrenal Tumor
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iodometomidate I-123, R- (also known as ) is phenylethylimidazole derivative studied as a diagnostic agent for adrenal imaging. Iodometomidate is a highly suitable tracer combining specific uptake in adrenocortical tissue with far lower radiation exposure compared to norcholesterol scintigraphy. Phase III clinical trial for Adrenal Gland Neoplasms imaging is currently ongoing.
Class (Stereo):
CHEMICAL (ACHIRAL)
Sulfacecole is an isoxazolylsulfanilamide derivative patented by Hoffmann -La Roche, F., und Co., A.-G. as antibacterial agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Iosimide is synthetic, nonionic, monomeric contrast medium patented by Schering A.-G. In clinical trial Iosimide exhibited no differences in comparison with Ioxaglate with respect to the contrast, the neurological status or the liver or renal tolerance. In examining cardiovascular tolerance there is only a slight tendency toward liver changes with Iosimide. Examination of the general tolerance, however, shows a statistically significant lower incidence of sensation of heat and pain with iosimide than with ioxaglate.
Status:
Investigational
Source:
USAN:LOMOFUNGIN [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Lomofungin, a natural product compound first isolated from the soil-dwelling Gram-positive bacteria Streptomyces lomodensis. Lomofungin has a broad antibacterial and antifungal spectrum, being active against gram-positive and gram-negative bacteria, yeasts, and other fungi. It prevents RNA synthesis by a direct interaction with the bacterial DNA-dependent ribonucleic acid (RNA) polymerase and not with the template or substrate. Lomofungin was identified as an inhibitor of botulinum neurotoxin light chain protease and as a potential therapeutic for myotonic dystrophy type 1. Lomofungin inhibited HIV-1 replication in peripheral blood mononuclear cells.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Repromicin is a compound that was reported in the literature in the 1990’s. Repromicin derivatives were found to have potent antibacterial activity against the Gram-negative pathogen Pasteurella multocida and Pasteurella heamolytica (in vitro and in vivo). Subcutaneous administration (single dose) in animals was found to control induced pasteurellosis (in swine) and induced respiratory disease (in cattle).
Class (Stereo):
CHEMICAL (ABSOLUTE)
Inocoterone acetate (USAN) (also known as RU-38882, RU-882) is the acetate ester of inocoterone a steroid-like nonsteroidal antiandrogen (NSAA) that was developed for topical administration to treat acne but was never marketed. Inocoterone acetate is actually not a silent antagonist of the androgen receptor but rather a weak partial agonist, similarly to steroidal antiandrogens like cyproterone acetate. In this double-blind study of 126 male subjects with acne, a topical solution of the antiandrogen inocoterone produced a modest but statistically significant reduction in the number of inflammatory acne lesions.
Class (Stereo):
CHEMICAL (ACHIRAL)
Piponulfan is neutral, difunctional alkylating derivative of piperazine. This agent was studied for their antineoplastic activity. Piposulfan has been found to be active against the following mouse tumors: sarcoma 180, carcinoma 755, and leukemia 1210. In patients with polycythemia piposulfan produced a response rate similar to that seen with pipobroman, busulfan, and triethylene melamine. However, piposulfan produces noticeably less toxicity than standard recommended doses of either busulfan or triethylene melamine. Various degrees of therapeutie remissions were seen in patients with malignant lymphomas, acute and chronic leukemia, multiple myeloma, adenocarcinomas, epidermoid carcinomas, and various types of sarcomas. The most common adverse reactions to piposulfan involved the hematopoietic (bone marrow depression) and gastrointestinal organs.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Pentamorphone was developed as a highly potent opioid with rapid onset and short duration of action that has been reported to produce analgesia with limited depression of ventilation. Pentamorphone participated in a clinical trial for the management of postoperative pain. However, no acute cardiorespiratory changes were observed. The drug was ineffective for treating acute postoperative pain after major surgery. In addition, was shown that pentamorphone, 10 micrograms/kg, does not seem to offer any significant advantage over opioids currently used for anesthesia in patients undergoing elective coronary artery bypass grafting (CABG). That is why its further development was discontinued.
